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Background: Juvenile dermatomyositis (JDM) is a rare autoimmune inflammatory disorder associated with significant
morbidity and mortality. International collaboration is necessary to better understand the pathogenesis of the disease,
response to treatment and long-term outcome. To aid international collaboration, it is essential to have a core set of
data that all researchers and clinicians collect in a standardised way for clinical purposes and for research. This should
include demographic details, diagnostic data and measures of disease activity, investigations and treatment. Variables in
existing clinical registries have been compared to produce a provisional data set for JDM. We now aim to develop this
into a consensus-approved minimum core dataset, tested in a wider setting, with the objective of achieving
international agreement.
Methods/Design: A two-stage bespoke Delphi-process will engage the opinion of a large number of key stakeholders
through Email distribution via established international paediatric rheumatology and myositis organisations. This,
together with a formalised patient/parent participation process will help inform a consensus meeting of international
experts that will utilise a nominal group technique (NGT). The resulting proposed minimal dataset will be tested for
feasibility within existing database infrastructures. The developed minimal dataset will be sent to all internationally
representative collaborators for final comment. The participants of the expert consensus group will be asked to
draw together these comments, ratify and ‘sign off’ the final minimal dataset.
Discussion: An internationally agreed minimal dataset has the potential to significantly enhance collaboration,
allow effective communication between groups, provide a minimal standard of care and enable analysis of the
largest possible number of JDM patients to provide a greater understanding of this disease. The final approved
minimum core dataset could be rapidly incorporated into national and international collaborative efforts, including
existing prospective databases, and be available for use in randomised controlled trials and for treatment/protocol
comparisons in cohort studies.
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It is recognised that an internationally agreed core data-
set for use in routine clinical care could have numerous
potential benefits for patients with this rare disease, with
the additional advantage of informing future research
[1]. The goals of this study are to reach international
consensus on a minimal dataset (clinical, laboratory and
patient/parent reported measures) for patients with ju-
venile dermatomyositis (JDM), which are practical, but
cover the key variables that allow accurate assessment of
disease activity and would measure change, such as re-
sponse to treatment. Such a core set could then be rapidly
incorporated into national and international collaborative
efforts. To date, 2 distinct but overlapping core sets for
JDM have been developed for use in clinical trials by the
International Myositis and Clinical Studies (IMACS)
group [2–4] and the Paediatric Rheumatology Inter-
national Trials Organisation (PRINTO) [5–7]. These ex-
cellent tools have been principally designed for research
and can be difficult to use in routine clinical practice due
to time constraints. Our aim is to compliment these core
sets with a separate internationally agreed minimal dataset
for use in clinical practice. The key achievable objective of
this study is for the developed minimal dataset to be
recognised and accepted internationally to allow data col-
lection over time on sufficient numbers of JDM patients.
In order to achieve this, a formal consensus-driven meth-
odology is required of all stakeholders.
Background work to this proposal is described elsewhere
[1]. In brief, a working group of five JDM experts (CP,
LW, AH, AR, LM) from the UK, Italy and Canada, repre-
sentative of the major groups studying JDM and maintain-
ing databases, scrutinised clinical and laboratory variables
contained within current national and international col-
laborative databases. Variables contained within 2 or more
databases were considered for inclusion in the provisional
minimal dataset, informed by a literature search and de-
tailed analysis of the UK Juvenile Dermatomyositis Cohort
and Biomarker Study (JDCBS) [1, 8].
Details of this project have been included in the Core
Outcome Measures in Effectiveness Trials (COMET) ini-
tiative database [9, 10]. In addition to close collaboration
with COMET, our group has sought advice from senior
members of the OMERACT (Outcome Measures in
Rheumatology) collaboration, who are renowned for
their work relating to outcome standardisation [11, 12].
Methods/Design
A provisional dataset for JDM, developed through a for-
mal process [1] has been used as a template to aid a
structured multi-stage consensus process. The Delphi
technique [13–15] has been used to gain the opinion of
large groups of internationally representative clinicians
caring for children and young people with JDM. This,together with a stepwise approach to gain the opinion of
patients/parents, will help inform a detailed face-to-face
nominal group consensus process by internationally rep-
resentative JDM experts.
Stage 1a – Delphi process to gain clinician opinion
A 2-stage survey technique (Delphi 1 and Delphi 2; with
each stage building on the proceeding one) has been
adopted, so that anonymous responses are obtained with
equal influence to all individual participants [13–15]. An
initial list of all potential variables was obtained from the
provisional minimal database produced by this group [1]
with outcomes listed individually but grouped under the
relevant domain to aid interpretation by clinicians. Out-
comes identified as patient/parent reported outcome
measures or validated tools of muscle strength measure-
ment [16] were presented within the appropriate domain
as use of the tool rather than as individual components
of the tool. However, in order to avoid discussions at this
stage around which tool/instrument is better for meas-
urement as opposed to another tool, an initial question
asked participants how important they rate the use of a
tool (without specifying which tool) to measure a certain
domain, such as muscle strength or skin involvement. If
they considered a tool to be important, they were asked
which tool they favoured.
The list of variables was reviewed and approved by all
authors as well as the research steering committee or
leading representatives of each of the principal partner
organisations (detailed in Table 1), including the Inter-
national Myositis and Clinical Studies group – IMACS
[4], Childhood Arthritis and Rheumatology Research Al-
liance – CARRA [17], Juvenile Dermatomyositis Re-
search Group – JDRG (UK and Ireland), [18], Paediatric
Rheumatology European Society – PReS JDM working
party [19], and the Paediatric Rheumatology INter-
national Trials Organisation – PRINTO [7]. After modi-
fications addressing feedback from these groups, the list
(shown in Table 2) was formatted into a bespoke elec-
tronic questionnaire. The UK Paediatric Rheumatology
Trainees’ Group and individuals from outside the UK se-
lected by members of the JDM Minimal Dataset Steering
Committee, piloted the questionnaire to determine average
time taken to complete and readability of the questions.
Participant details
Participation for the Delphi surveys was invited via
membership of IMACS, CARRA, JDRG, PReS JDM
working party and PRINTO; representative of inter-
national paediatric rheumatology and myositis specialty
groups. These organisations include clinicians (clinical
academic and non-academic), scientists and allied health
professionals with expertise in paediatric rheumatological
conditions and juvenile-onset and adult-onset myositis
Table 1 Details of collaborative groups and partner organisations
Collaborative organisation Membership Main geographical area covered Collaborative role in study
Juvenile Dermatomyositis Research
Group, JDRG (UK and Ireland) [18]
Multi-disciplinary healthcare professionals and
scientists in the field of Paediatric Rheumatology;
representative of all major UK paediatric
rheumatology centres. JDRG members are all
contributors to, and investigators in, the Juvenile
Dermatomyositis Cohort and Biomarker Study,
JDCBS [8]
UK and Ireland ▪ Delphi survey Email distribution
▪ Representation in NGT meeting
▪ Scrutinising data collection (Stage 3)
▪ Aid dissemination of study results
▪ Steering committee – study oversight
▪ Patient/parent representation: steering committee
and facilitated groups
Childhood Arthritis and Rheumatology Research
Alliance, CARRA [17]
Paediatric rheumatologists and researchers throughout
North America (n > 390); a proportion of whom have
an interest in JDM and others more experienced in
other areas of paediatric rheumatology
North America ▪ Delphi surveys Email distribution
▪ Representation in NGT meeting and provisional
minimal dataset
▪ Aid dissemination of study results
Paediatric Rheumatology INternational
Trials Organisation, PRINTO [7]
International research network with the aim of
coordinating clinical trials and outcome studies
in paediatric rheumatology
Initially a European collaboration
but now includes > 50 countries
and > 350 centres worldwide
▪ Delphi surveys via E-mail distribution
▪ Representation in NGT meeting and provisional
minimal dataset
▪ Aid dissemination of study results
Paediatric Rheumatology European
Society, PReS [19]
European scientific society for healthcare professionals
in the field of paediatric rheumatology. The PReS
JDM working group is a sub-group of this organisation
that invites individuals with an interest or expertise
in JDM
All European countries (EU and
non-EU), extended to the Middle
East. Associate members welcome
worldwide
▪ Delphi surveys via Email distribution
▪ Representation in NGT meeting
▪ Aid dissemination of study results
International Myositis Assessment
and Clinical Studies group, IMACS [4]
Coalition of healthcare providers and researchers
with an interest in myositis syndromes. Myositis
syndromes include JDM but also other inflammatory
myopathies that are more common in adult patients
Part of the NIH science research
programme, USA but welcomes
members globally
▪ Delphi surveys via Email distribution
▪ Representation in NGT meeting
▪ Aid dissemination of study results
Euromyositis [39, 40] European initiative leading to the creation of a web-
based registry for adult myositis patients, recently ex
panded to include paediatrics
Initially European counties (EU and
non-EU) expanded to include other
collaborators outside Europe (Japan,
Mexico, China, US)
▪ Collaborators in formation of a minimal dataset
▪ Representation in NGT meeting
▪ Testing data collection over time (Stage 3, potential)
OMERACT [11] An independent initiative of international health
professionals interested in outcome measures in
rheumatology
North America, Europe and
Asia-Pacific
▪ Advisory role in development of Delphi survey and
in patient involvement
▪ Representation in NGT meeting











Table 2 Summary of questions asked in clinician survey compared to the parent and patient questionnaires
Domain Questions asked of healthcare professionals
in Delphi 1 and 2
Questions asked in parent questionnaire Questions asked in young person’s questionnaire
General format of questionnaire Two separate sections: Section A – when patient
seen for their first visit only; Section B – all visits (first
and subsequent). Asked to rate importance of each
variable on a 1–9 scale separately for clinical use and
for research
Asked to rate: How important do you think each
one of these is when thinking about how well
or unwell your child is due to JDM? (“not that
important”/ “important”/or “really important”).
Not asked separately about clinical/research
Asked to rate: How important do you think each
one of these is when thinking about how well
or unwell you are due to JDM (“not that important”/
“important”/“really important”) Not asked separately
about clinical/research
General questions on collecting
and storing information and/or
specimens
N/A Asked to rate how important they think it is for
all doctors and nurses/therapists to collect key
information in the same way when they are
looking after children with juvenile dermatomyositis
(JDM)
Asked to rate how important they think it is for
all doctors and nurses/therapists to collect key
information in the same way when they are
looking after children with JDM
How important do you rate storing specimens at
diagnosis for other biomarkers? (eg., DNA/serum/any
other material)a
Asked to rate how important they think it is to
store the type of information collected in clinic
in a research database
Asked to rate how important they think it is to
store the type of information collected in clinic
in a research database




Family history Of autoimmune disease N/A N/A
Of neuromuscular disease
Diagnostic data (general) Age of onset of JDM N/A N/A
Age of diagnosis of JDM
MUSCLE – Diagnostic/activity
data
Presence of symmetrical proximal muscle weakness:
at diagnosis (section A) and every visit (section B)
Asking you if your child has any weakness Asking if you have any weakness
Presence of other muscle weakness (eg., distal or
asymmetrical): section B only
Use of a validated tool to score muscle strength
and/or function (options for different muscle
strength scores)a
Testing to see how strong your child is Testing to see how strong you are
SKIN – Diagnostic/activity data Heliotrope rash (sections A and B) Asking you if your child has any skin rashes Asking if you have any skin rashes
Gottron’s papules/Gottron’s sign (sections A and B)
Nail-fold capillary changes (sections A and B)
Other characteristic JDM rash
Use of a validated skin tool for JDM (options given
to choose specific tools)a
Looking for rashes or skin signs that may suggest
active JDM
Looking for rashes or skin signs that may suggest
active JDM
SKIN – Additional activity data


























due to myositis – asked in section
B only of clinician survey, plus
patient/parent questionnaires
Musculoskeletal involvement (specific questions
added for arthritis/contractures)a
Asking if your child has any muscle or joint pains Asking if you have any muscle or joint pains
Looking for swelling in any of the joints Looking for swelling in any of the joints
Gastrointestinal involvement (specific questions
added for dysphagia/abdominal pain or GI
ulceration)a
Asking if your child has any difficulty with
swallowing/eating or if they have tummy pain
Asking if you have any difficulty with eating or
if you have tummy pain
Pulmonary involvement suggesting interstitial lung
disease
Asking if your child has any shortness of breath
or chest pain that may be related to JDM
Asking if you have any shortness of breath or
chest pain that may be related to JDM
Cardiac involvement
CONSTITUTIONAL SYMPTOMS
due to myositis – asked in section
B only of clinician survey and in
patient/parent questionnaire
Fever (>38 °C) due to myositis N/A N/A
Weight loss (>5 %) due to myositis N/A N/A
Fatigue due to myositis Asking if your child feels tired due to JDM Asking if you feel tired due to JDM
Asking how tired your child feels using a formal
“fatigue scale”
Asking how tired you feel using a formal ‘fatigue
scale’
Irritability due to myositis Asking if your child feels irritable or miserable due
to JDM
Asking if you feel irritable or miserable due to JDM
Raynaud’s phenomenon Asking if your child gets colour changes in their
hands in cold weather
Asking if you get colour changes in your hands in
cold weather
Growth Height of patient (section B only) Checking how well your child is growing (height) Checking how well you are growing
Weight of patient (section B only) Asking about any weight loss and checking your
child’s weight
Asking about any weight loss and checking your
weight
Development/puberty N/A Asking about how your child is developing or how
puberty is progressing
Asking about how you are developing or how
puberty is progressing
Other information Presence of malignancy (section B only) N/A N/A
Patient having ongoing follow-up at this centre?
(If no: options given for reason why)a
Global disease activity Asking your doctor to mark on a 0–10 cm scale
how well or unwell they think your child has been
Asking your doctor to mark on a 0–10 cm scale











Table 2 Summary of questions asked in clinician survey compared to the parent and patient questionnaires (Continued)
Use of a physician-scored measure of global disease
activity - such as physician Visual Analogue Scale;
VAS (specific choices for activity scores given)a
based on what you tell them and what they see
at your clinic visit
Patient/parent Reported Outcome
Measures (PROMs), Quality of Life/
School issues
Use of a patient/parent reported outcome measure
of disease activity or use of a validated measure of
function (such as patient VAS/CHAQ) and/or a tool
to measure Quality of Life (QoL) (specific choices
given)a
Asking you or your child to complete a questionnaire
that looks at how easy or difficult it is for them to
do things like get dressed, have a bath, do activities
Asking you or to complete a list of questions
that look at how easy or difficult it is for you to
do things like get dressed, have a bath, do activities
Asking you/your child to mark on a 0–10 cm scale
how well or unwell your child has been over the
last 4 weeks
Asking you to mark on a 0–10 cm scale how
well or unwell you have been over the last
4 weeks due to JDM
Asking you/your child to mark on a 0–-10 cm scale
how much pain your child has had in the last
4 weeks due to JDM
Asking you to mark on a 0–10 cm scale how
much pain you have had in the last 4 weeks
due to JDM
Asking how many days your child has missed school
or college due to JDM
Asking how many days you have missed school
or college due to JDM
Asking more questions about your child’s school –
how are things? Are they able to keep up with
peers?
Asking more questions about school – how are
things? Are you able to keep up with your peers?
Asking your child how they feel emotionally in
relation to their JDM (questions relating to Quality
of Life or mood)
Asking about your feelings in relation to your JDM
INVESTIGATIONS: diagnostic data/
disease activity data
Elevation of muscle enzymes at diagnosis (section A)
or later in disease course (section B). (Questions asked
about which specific enzymes to measure)a
Taking blood tests to monitor how active the disease is Taking blood tests to monitor how active the
disease is
Electromyography (EMG) changes of myositis at
diagnosis (section A)
Muscle biopsy evidence of myositis at diagnosis
(section A)
Magnetic Resonance Imaging (MRI) changes of
myositis at diagnosis (section A)
Asking your child to have a scan such as an MRI
scan of their muscles to monitor the disease
Asking you to have a scan such as an MRI scan
of your muscles
Section B only: abnormal investigations (imaging,
histology or cardio-pulmonary function tests indicating
flare of myositis). If “yes,” tick which investigations are
abnormal
Anti-nuclear Antibody (ANA) positivity at diagnosis
(section A only)
Myositis specific antibody (MSA) positive at
diagnosis (section A only)
Myositis associated antibody (MAA) positivity at
diagnosis (section A only)
Treatment Date treatment started (mm/yyyy) Asking specific questions about your child’s
medicines and how they make them feel? Any
unwanted effects?
Asking specific questions about your medicines












Table 2 Summary of questions asked in clinician survey compared to the parent and patient questionnaires (Continued)
Patient taking steroids? Yes/No (options for type
of steroid given)a
Asking you about the medicines your child is taking
at the moment
Asking you about the medicines you are taking
at the moment
Patient taking a Disease Modifying Anti-Rheumatic
Drug (DMARD)? (Not including biologic DMARDS)
Yes/No (with option to select name of drug from a
list)
Patient taking a biologic? Yes/No (with option to select
name of drug from a list)
Patient having physiotherapy and/or occupational
therapy?
Asking you if your child is doing any physiotherapy
exercises
Asking you if you are doing your physiotherapy
exercises
Other questions To determine practice and experience - primary role,
patient group, number of paediatric/adult patients
under their care, geographical region of practice and
membership of societies/professional bodies
How would you prefer information to be asked of
you? (eg., in clinic, questionnaire before clinic,
questionnaire before you come to clinic)
How would you prefer information to be asked of
you? (eg., in clinic, questionnaire before clinic,
questionnaire before you come to clinic)
Further information Are there any variables that you think are important
for clinical care that are not currently included in the
list above? If so, please state what these are (same
question also asked separately for variables important
for research)
Are there any other key questions that we have
missed but that you think it is important for us
to ask when you come to clinic, thinking about
how well/unwell you/your child is? If so, what key
questions are they?
Are there any other key questions that we have
missed but that you think are important for us
to ask when you come to clinic, thinking about
how well or unwell you are? If so, what key
questions are they?
Is there anything in this list (or from your experience
of bringing your child to clinic) that you do not
think should be included or you think your child
does not like? If so, what? Why do you think that
these questions should not be included?
Is there anything in this list (or from your experience
of coming to clinic) that you do not like? If so, what?
Why do you think that these questions should not
be included?
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and invited to participate in the two web-based question-
naires using a bespoke Delphi system. The only exception
to this was the PRINTO membership. In view of the fact
that PRINTO is a large and heterogeneous organisation
with over 900 individual members, the PRINTO directors
(approximately 400 members) were contacted. PRINTO
directors represent all of the major paediatric rheumatol-
ogy centres among member countries. Many Email recipi-
ents are part of more than one research organisation and
in this case, they were asked to complete each survey
round once only and identify which other groups they are
members of (and, therefore, potentially part of more than
one mailing).
Delphi round 1
The study objectives were clearly stated including what
was expected of each participant. Participants were
reminded of the importance of completing the entire Del-
phi process and asked to complete each round within
6weeks of receipt of Email. Reminder Emails were sent on
a fortnightly basis to aid completion of each round, with
phrasing of reminders considered to maximise the re-
sponse rates [20]. Participants who agreed to take part
were asked to register, allowing a unique identifier to be
allocated to enable tracking of attrition at each round and
identification of the research group that the participant
was responding from (IMACS, CARRA, PRINTO, PReS
JDM working group or the UK JDRG). Contributors were
asked to specify their predominant clinical role (clinician/
scientist/allied health professional/trainee), their specialty
(specialist or major interest in rheumatology/ neurology/
dermatology/immunology/other), the age of patient that
they predominantly care for (adult/paediatric) their experi-
ence in the specialty/condition (≥ or < 10 years), and their
region/country of practice. Participants were encouraged
to answer the web-based survey to reflect their individual
practice. However, in recognition that some respondents
(particularly PRINTO directors) may answer on behalf of
their centre, a question was asked to ascertain if they were
answering as an individual reflecting their own practice, or
on behalf of their department/centre (stating name of
centre). Participants were not able to identify other partici-
pants or individual responses. Owing to their involvement
in the study design and Delphi exercise, members of the
JDM Minimal Dataset Steering Committee were not asked
to participate in the Delphi surveys themselves, but en-
couraged maximal engagement and participation of indi-
viduals within the international research groups that they
represented.
Survey format
The outcome of this process will be to determine which
variables clinicians perceive are important to include inone single minimal dataset that will be useful for clinical
purposes and also inform research. However, within the
survey, this question was divided into two separate sec-
tions, asking participants to rate in a structured format
the importance of each variable for use in clinical prac-
tice, and separately, for its benefit in research. Each par-
ticipant will be asked to score each of the outcomes
listed using the Grade of Recommendations Assessment,
Development and Evaluation (GRADE) scale of 1–9,
with 1–3 labelled as “of low importance,” 4–6 labelled as
“important but not critical for decision making” and 7–-
9 labelled as “critical for decision making” [21]. Partici-
pants will have the option of selecting “unable to score”
if they feel unable to comment based on their clinical
experience, but they will be forced to answer each ques-
tion before they move to the next stage of the question-
naire. For questions relating to investigations, in Delphi
1, participants will be asked whether each variable is ac-
cessible (easily available) to them in routine clinical
practice in their hospital/country; given the option “yes,”
“no” or “unable to comment”.
Participants who save an incomplete questionnaire will
be contacted to encourage completion. Each participant
will be given the opportunity to submit details of add-
itional data items that they think should be included for
clinical or research reasons (and reasons why) that are
not part of the provisional data set. They will also be
given the opportunity to submit written comments re-
garding those that have been included, including their
opinion as to whether variables have been included that
they perceive unnecessary, and if so, why.
Analysis of round 1
Any additional outcomes suggested by participants in Del-
phi 1 will be carefully reviewed and coded by investigators
to determine if they represent new outcomes not already
incorporated in the questionnaire. Any identified will be
added to the questionnaire for Delphi 2. For each out-
come, the number of participants who have scored the
outcome and the distribution of scores (as percentage who
have scored each GRADE level) will be summarised. In
view of the fact that the web-linked processes will involve
participants with varying experience in JDM, any variables
thought not to be useful will be noted at this stage but not
specifically removed; respondents’ opinions will be re-
corded to help inform subsequent processes. The number
of participants responding will be assessed following Del-
phi closure and results presented as total number of regis-
trations, total number who completed the round and total
number compared to potential respondents.
Delphi round 2
Participants registering during part 1 will be invited to
participate in the Delphi 2 survey and will thereby form
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round 2, participants will be shown their score from
round1 for each question (highlighted in every row of
the Delphi 2) in addition to the total number of respon-
dents for each question and the percentage of people
responding to each ranking of importance (1–9) of the
9-point Likert scale. They will be asked to consider re-
sponses from the group and asked to verify that their
round-1 response did indeed reflect their opinion, or
given the opportunity to change or expand their re-
sponse by re-scoring the outcome. Any changes to
scores will be documented.
Analysis of round 2
Round-1 responses will be compared between those who
responded to both Delphi round1 and round2 against
those who responded to Delphi round 1 only (but failed
to respond to round2) to look for response bias. The
total number of respondents to round2 will be recorded.
For each outcome, the number of participants who have
scored the outcome and the distribution of scores will
be summarised. Content analysis will be used to code
and describe written comments and responses. During
the analysis of round2, results will be prepared for pres-
entation at the consensus meeting within 3 groups:
“consensus in,” “consensus out” or equivocal.
Definition of consensus
1. “Consensus in” - consensus that the outcome should
be included in the minimal dataset; defined as greater
than 70 % of participants scoring 7–9; “critical for
decision making”.
2. “Consensus out” - consensus that the outcome
should not be included in the minimal dataset;
defined as greater than 70 % of participants scoring
as 1–3; “low importance”.
3. All other combinations will be presented as
“equivocal”.
Seventy percent consensus has been chosen as a pre-
defined cut off for this stage. The OMERACT handbook
and COMET management group use this consensus
definition.
Sample size
There is currently no standard method for sample size
calculation in Delphi processes and sample size esti-
mates for this study have been carried out by a prag-
matic approach considering responses from similar
studies using a Delphi web-based survey distributed via
rheumatological collaborations. Summating the current
estimated membership of each collaborative working
group (IMACS, CARRA, PRINTO, PReS JDM workingparty, JDRG) totals over 1000 members, but it is recog-
nised that the majority of members will belong to more
than one organisation and membership lists include re-
tired or non-active members. Some organisations, such as
IMACS, include many specialists in adult myositis who
may feel less inclined to respond to a paediatric-focused
study. Based on observed response rate from similar pro-
cesses in paediatric rheumatology (49.8–84 %) [22–26]
and attrition rate between 1.6 and 33 % [24–26], with less
attrition in recent years, it is anticipated that the response
rate for round1 will be approximately 150–200 partici-
pants with a 10 % attrition rate between rounds 1 and 2.
Stage 1b – patient/parent engagement/consultation
A formal stepwise process for patient/parent participa-
tion will take place, distinct but alongside the Delphi
process engaging clinicians and healthcare professionals,
with both processes feeding into the nominal group con-
sensus meeting of experts.
Currently, there is very little research published in
JDM engaging patient/parent opinion. Our group has
sought advice from senior members of COMET [9] and
OMERACT [11] and consumer representatives of the
National Institute for Health Research (NIHR) Clinical
Research Network (CRN): Children/Arthritis Research
UK Paediatric Rheumatology Clinical Studies Group
(CSG) [27]. A sub-group of this organisation is the JDM
Topic Specific Group (TSG), within which members of
our group have been working to engage patients and
parents in JDM research. Through this infrastructure,
the opinions of young people with JDM and their par-
ents/carers have been obtained, including checking and
commenting on study information leaflets and patient/
parent questionnaires. Our group is working directly
with patient/parent groups within the UK and North
America; Myositis UK [28] and Cure JM Foundation
[29], who have agreed to distribute an electronic patient/
parent questionnaire via their websites. In the UK, the
research infrastructure within the JDRG allows patients
and parents to be approached by the clinicians/health-
care professionals caring for them within their local
centre [8, 18]. An attempt will be made by our collabo-
rators to replicate the UK model in other counties to en-
sure international representation as far as is possible.
Translation will take place as appropriate.
Patient and Parent Questionnaire
The Delhi survey (sent to clinicians and healthcare pro-
fessionals) has been reviewed by members of the JDM
minimal dataset management committee and steering
committee for relevance to patients and parents. There
are many variables within this matrix that are not dir-
ectly of interest to patients and parents (such as demo-
graphics) but others (such as patient/parent reported
McCann et al. Trials  (2015) 16:268 Page 10 of 15outcome measures) that are particularly relevant. Hence,
a separate provisional questionnaire was designed for pa-
tients/parents to complete (Table 2), including some
specific variables on school/quality of life felt to be im-
portant by young people when commenting on the ques-
tionnaires. A similar format for scoring responses to
answers has been used as within the Delphi survey
(GRADE scale) but simplified into three categories: “not
that important,” “important,” or “really important”.
Questionnaires were designed for screen-based modes of
administration as well as paper format, depending on
patient/parent preference. Electronic entry will be en-
couraged but patients/parents can choose to complete a
paper questionnaire that will subsequently be entered
into the electronic system by research staff.
Information leaflets were prepared for parents and for
children/young people aged 8–11 years, 12–15 years,
and 16+ years of age. Readability scores were used to
check age appropriateness of the questionnaire and in-
formation leaflets [30, 31]. In addition, to ensure that
the study documents were understandable to patients
and parents, opinions were sought within the UK from
the COMET [9] Patient and Public Involvement Coord-
inator, research nurses experienced in patient/parent in-
volvement, consumer representatives of the Medicines
for Children Research Network (MCRN) Clinical Studies
Group [27], the Parent Group of the British Society for
Paediatric and Adolescent Rheumatology (BSPAR) [32],
young people participating in the NIHR CRN Young
Person’s Advisory Group [33] and young people with
JDM participating in a newly formed UK JDM Young
Person’s Group, linked to the JDM TSG [27]. Subse-
quently, the final questionnaire, age-appropriate infor-
mation leaflets, consent forms and assent forms were
submitted to the NHS Integrated Research Application
System and approved. The parent information leaflets
make it clear that parents can either consent to be in-
volved in the study themselves and/or consent for their
child to participate in the study.
Participants
Participation will be open to the following groups:
a. Any child or young person with JDM
b. Any adult who had JDM as a child
c. Any parent of a child with JDM
There is no restriction in numbers and no exclusions
within these groups. However, it is anticipated that chil-
dren younger than 8 years of age are likely to be repre-
sented by their parents/carers and it is recognised that
reliability or validity of child-reported measures at this
age are often questionable [30]. Every effort will be made
to translate information/questionnaires into the languageof participants if needed or to engage translators. Pa-
tients with adult-onset myositis will not be allowed to
participate, as there are significant differences in the dis-
ease processes and prognosis between adult-onset and
juvenile-onset myositis. Adult-onset disease is defined in
the UK as occurring after 16 years of age, and in the
USA as occurring after 18 years of age.
Distribution of questionnaires
Information about the study and questionnaires will be
distributed in the UK as follows:
a) Following site-specific ethics approval for this study
at each major paediatric rheumatology centre
already participating in the Juvenile Dermatomyositis
Cohort and Biomarker Study (UK and Ireland) [8],
parents and patients will be approached by their
local doctors/nurses and asked whether they would
be interested in taking part in this study. These doctors
and nurses are part of the JDRG [18], including 14
major paediatric rheumatology centres in the UK, and
are fully informed about the study and trained in Good
Clinical Practice (GCP). After allowing time for
consideration and the opportunity to ask questions,
patients and or parents will be asked to complete a
questionnaire when they come for their clinic
appointment or at home.
b) An advert will be submitted to patient/parent
myositis organisations [28, 29] inviting participation.
Patients and parents will be asked to complete a
secure web-based questionnaire once they have
confirmed that they have read the information leaflets
and signed the consent form.
c) Individuals who have previously expressed an
interest in becoming involved in future research in
JDM by contacting the UK Juvenile
Dermatomyositis Research Group and/or by
participation in parent/young peoples’ groups will be
contacted by Email and invited to participate in this
project.
Informed consent will be taken from each participant.
Collaborators in Italy and the Netherlands will attempt to
replicate this process (with country-specific ethics ap-
proval and translation as needed). Patients and parents in
North America or elsewhere will be able to participate via
electronic links provided by collaboration with patient and
parent groups – Myositis UK [28] and Cure JM [29], with
the recognised limitation that the questionnaires will only
be provided in English-language format.
Currently, a number of patient and parent reported
outcome measures are used in clinical practice and re-
search in JDM [2, 3, 5, 6, 16, 34, 35]. Many of these tools
have been developed for other rheumatological conditions
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recently, a JDM-specific tool – the Juvenile Dermatomyo-
sitis Multidimensional Assessment Report – has been de-
veloped and is currently being validated [36]. Young
people with JDM participating in a newly formed UK JDM
Young Person’s Group, linked to the JDM TSG [27], will
be invited to participate in a focus group asking them to
specifically consider various Patient Reported Outcome
Measures currently available to determine if there is a
preference for particular tools. Likewise, parents partici-
pating in a newly formed UK Parent Group, linked to the
JDM TSG [27], will be asked to consider Parent Reported
Outcome Measures. A detailed summary of the opinions
of patients/parents will be prepared for participants of the
consensus meeting and presented, with individual com-
ments anonymised, to the group prior to and during the
meeting.
All patient/parent participants completing the ques-
tionnaire will be asked if they would be willing to poten-
tially participate in further stages of the study, and if so,
asked to provide their contact details. Following analysis
of the Delphi survey, they may be asked to consider spe-
cific questions or issues relating to the acceptability of
completing variables in clinical practice, to help inform
the consensus meeting, such as:
1. Time taken to complete each variable for the
patient/parent.
2. Ways of completing variables that may make them
more acceptable (for example, use of web-based
questionnaires that can be complete before clinic).
3. Practical implications of completing each variable
(for example, volume of blood needed for the test if
extra blood tests indicated).
4. Consideration of validated patient/parent reported
outcome measures that may form part of a minimal
dataset to determine if there is a preference for
particular patient/parent reported measures.
Consideration will be given to direct patient/parent in-
volvement and representation during the nominal group
consensus meeting, particularly if there are a few pa-
tient/parent representatives who stand out in being able
to represent views of the group. If patients/parents are
involved in the consensus meeting they will be fully sup-
ported throughout the process by the COMET Patient
and Public Involvement Coordinator.
Analysis of data
For each questionoutcome, the number (percentage) of
participants who have scored the outcome as important
and the distribution of scores will be summarised. Con-
tent analysis will be used to code and describe written
comments with individual comments anonymised. Adetailed summary of the opinions of patients/parents
will be prepared for participants of the consensus meet-
ing. Participants of the consensus meeting will be sent
this information prior to the meeting and also be
reminded of specific points relevant to variables during
the meeting.
Other studies that members of our group are involved
with are also engaging patient/parent participation that
may be relevant to our study. For example, the
European-wide FP7 funded SHARE (Single Hub and Ac-
cess Point for Paediatric Rheumatology in Europe) project
[37] led by Professor Nico Wulffraat, Utrecht, Netherlands,
which aims to define a standard of care for paediatric
rheumatology throughout Europe, includes a JDM work-
stream. Thus, findings from this will also be summarized
and be available for review by members of the nominal
group consensus meeting.
Stage 2 – Consensus meeting using the nominal group
technique
The results of the Delphi exercise and patient/parent
opinion will be used to inform Stage 2 of the study; a 2-
day international consensus meeting of senior represen-
tative international experts in JDM tasked with under-
taking nominal group consensus formation.
Participants
The consensus meeting will include 15–20 healthcare
professionals/scientists who are experts in JDM; many of
whom are experienced in NGT. Patient/parent represen-
tation will be considered, as above. The total number of
participants has come from recommendations for ideal
NGT consensus group size [38] and suggestions from
the COMET [9]/OMERACT [11] collaborative groups.
Individual experts have been chosen by the JDM steer-
ing committee with consideration of the following criteria:
1. Individual expertise: each individual is a recognised
expert in the field of myositis.
2. Consideration of the wider groups that they lead or
represent – ensuring that the final group includes
representation from all international paediatric
rheumatology and myositis expert groups.
3. Geographically internationally representative of the
international paediatric rheumatology community.
4. Representative of the sub-specialty groups that care for
children with JDM including paediatric rheumatology,
neurology, dermatology and adult rheumatology.
Structure of meeting
Analysis of the Delphi surveys will determine which vari-
ables were thought to be important to include in a min-
imal dataset by the wider group (“consensus in”) and
which variables (“equivocal”) need more discussion within
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the parent/patient questionnaires will be presented along
with results of the Delphi (clinician opinion) for each vari-
able to all participants of the consensus process prior to
and during the meeting. Initially, members of the expert
group will be presented with those variables judged as
“consensus in” within the Delphi process to check for con-
sensus agreement within the expert group before proceed-
ing. It is anticipated that a quick decision can be made for
a number of the variables in this way, but that cer-
tain items will need more detailed discussion to ob-
tain consensus.
Nominal group technique (NGT) is a structured group
meeting that follows a prescribed sequence of problem-
solving steps [15], forcing equal participation among
members in generating information and achieving out-
comes. One non-voting participant, experienced in NGT
but neutral to the study, will act as a facilitator and en-
sure that the process is not taken over by any one indi-
vidual with strong views.
During the NGT process, the facilitator will frame the
question to be discussed and show data from the Delphi
surveys and patient/parent involvement relevant to that
question. Each participant will have the opportunity to
discuss his/her opinion for 1–2 minutes without inter-
ruption. Responses will be recorded and detailed notes
taken. Participants will be given the opportunity to vote
for their preferred response to each question. An agree-
ment of ≥ 80 % consensus of all attendees will be required
to consider each question as solved. If there is < 80 % con-
sensus, participants will once again be given the opportun-
ity to talk for 1–2 minutes. After discarding answers that
are clearly not preferred, there will be another round of
voting. The process will continue until there is consensus
or lack of consensus achieved for each question. The NGT
process will attempt to take into account feasibility of in-
cluding individual variables (determined by results of the
Delphi survey and patient/parent participation process) as
well as the validity reliability of variables (from published
literature) and the acceptability of the format of the data-
set including definitions/glossary (defined in the
provisional minimal dataset). Agreement with state-
ments will be summarised by percentage agreement
statistics.
Stage 3 – Testing the dataset in real-life clinical practice
The proposed minimal dataset developed in Stage 2 will
be tested for feasibility in Stage 3 of the study. This is to
ensure that each outcome variable is feasible to
complete in clinical practice and will directly inform
clinical care as well as having a research rationale. Clini-
cians will be asked to enter anonymised data prospect-
ively over time on at least 2 cases of JDM under their
care via already-established internationally accessiblesecure web-databases [8, 39, 40] that will be adapted to
incorporate questions asked within the developed min-
imal dataset. Each centre (hospital) has access to its own
data with coded information from the complete database
accessible with research steering committee approval.
Each patient is assigned a unique identification number
for research purposes and de-identified from personal
information such as name, address, and hospital num-
ber. Data are protected by login and password and trans-
fer of data encrypted. After allowing 6 months for data
entry into collaborating databases, coded data on JDM
patients will be made available for analysis. The study
statistician will develop an algorithm to scan the dataset,
flagging all missing observations, outlier and ill-coded
variables to allow completion/data cleaning. In this way,
Stage 3 will carefully assess whether the data entered
into prospective data collections by clinicians (who are
not necessarily experts in JDM) in real-world environ-
ments, is complete and accurate, as defined by the
provisional dataset definitions/glossary [1] or whether
clearer definition of variables are required. Definitions of
variables will be refined by the JDM minimal dataset
steering committee if needed, by Email or telephone
consensus, after data analysis. The developed minimal
dataset will be sent to the Chairs of all principal partner
organisations’ (IMACS, CARRA, PReS, PRINTO, JDRG)
individual research steering committees for final com-
ment. The NGT group will be asked to draw together
these comments and ratify and “sign off” the final min-
imal dataset.
Ethical approval
Ethical approval has been obtained from the IPHS Research
Ethics Committee (reference IPHS-1314-321). NHS Re-
search Ethics Committee approval has also been obtained
from the NRES Committee East Midlands (reference 14/
EM/1259; IRAS project ID 160667).
Ethical considerations
Stage 1a (Delphi survey) does not involve patient data
and simply involves consensus among clinicians
Stage 1b (patient/parent involvement) will be canvasing
opinion from patients (aged < 16 years of age) and their
parents, as well as patients (>16 years of age) who have
or previously had juvenile-onset myositis and parents
of children with JDM. NHS Research Ethics approval
obtained
Stage 2 (nominal group consensus) does not involve
patient data and simply involves consensus among
experts in myositis
Stage 3 will involve analysis of anonymised data after
piloting the minimal dataset in a proportion of patients
over a restricted period of time (6 months) via already
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country specific, and although it will involve
anonymised patient data, it is required for some
collaborators. Ethical approval is already obtained for
data collection within most of the organisations that
may collaborate at this stage including the UK JDCBS,
Euromyositis, the Gaslini Institute and CARRA. Other
participants will be able to enter data via Euromyositis
or obtain their own IRB approval. However, the study
is not dependent on IRB approval of these individual
countries, as sufficient patient numbers should be
achieved via use of established databases that already
include ethical approval. Our group will only have
access, through research steering committee
application, to secondary anonymised data collected
within these individual databases.Discussion
The Delphi process has the advantage of allowing infor-
mation to be exchanged between numerous individuals
who may be geographically dispersed [38]. However, the
advantage of face-to-face interaction is that it allows
identification of the reasons for disagreements between
individuals [38]. By using a combination of Delphi web-
based surveys and face-to-face interaction in an NGT
consensus group process, this study will obtain wide-
spread opinion from a large number of clinicians in
addition to the judgment of a small group of inter-
nationally renowned and representative group of experts
in JDM. Patient and parent participation will be ensured
via a structured process, including widespread distribu-
tion of a questionnaire and more detailed discussion
within established patient/parent groups in the UK. The
use of focus groups will allow stimulation of discussion
and comparison of experiences across participants,
whereas individual questionnaire responses will allow
obtainment of opinions without influence from peers
[30, 41]. In addition, consideration will be given to a
small number of patient/parent representatives partici-
pating in the consensus meeting, representing the views
of this group.
An internationally agreed minimal dataset has the po-
tential to significantly enhance collaboration, allow ef-
fective communication between groups, provide a
minimal standard of care and enable analysis of the lar-
gest possible number of JDM patients to provide a
greater understanding of this disease. A consensus-
driven, internationally approved minimum core dataset
could be rapidly incorporated into national and inter-
national collaborative efforts, including existing pro-
spective clinical databases, and be available for use in
randomised controlled trials and for treatment/protocol
comparisons in cohort studies.Study status
Currently at Stage 3: Delphi survey of clinicians and
consensus meeting completed. Patient/parent question-
naires ongoing.
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